The latest market research report published by Future Market Insights (FMI) sheds light on the promising trajectory of the global fuchs endothelial corneal dystrophy (FECD) market. According to the report, the market witnessed a remarkable surge, garnering a market value of US$ 180 Billion in 2023. Anticipated to maintain its upward trajectory, the market is projected to accumulate a staggering value of US$ 370 Billion by 2033, reflecting a robust CAGR of 7.5% during the forecast period.
Key factors driving this exponential growth include the escalating prevalence of Fuchs’ endothelial corneal dystrophy, a demographic shift marked by an increasing number of senior individuals, and a parallel rise in healthcare expenditure worldwide. Moreover, advancements in medical technology, coupled with a burgeoning demand for corneal transplantation, are poised to further fuel market expansion.
Get your Sample Report: https://www.futuremarketinsights.com/reports/sample/rep-gb-16243
Governmental and private organizations are intensifying efforts to raise awareness about eye disorders and promote corneal donation, which is expected to significantly contribute to market growth. Additionally, the surge in research focusing on cellular treatment techniques and the growing demand for comprehensive eye care services are anticipated to create lucrative opportunities within the fuchs endothelial corneal dystrophy market landscape.
The report provides comprehensive insights into the competitive landscape, market dynamics, and key trends shaping the global fuchs endothelial corneal dystrophy market. It offers actionable intelligence to industry stakeholders, enabling them to make informed decisions and capitalize on emerging opportunities.
Key Takeaways from the Market Study:
- FMI projects the global Fuchs Endothelial Corneal Dystrophy (FECD) market to expand at a 7.5% value CAGR by 2033
- The global Fuchs Endothelial Corneal Dystrophy (FECD) market is estimated at a market value of US$ 180 Billion
- The global Fuchs Endothelial Corneal Dystrophy (FECD) is expected to garner a market value of US$ 370 Billion
- As per Future Market Insights, the Asia Pacific is expected to grow at a CAGR of 7% in the assessment period 2023-2033.
- North America is expected is expected to grow at a CAGR of 7.4% in the assessment period 2023-2033.
- Europe is expected to grow at a CAGR of 7.3% in the assessment period 2023-2033.
- The hospitals segment is expected to hold the largest market share for lucrative Fuchs Endothelial Corneal Dystrophy (FECD) market in the forecast period 2023-2033.
“Asia-Pacific is predicted to rise over the projected period of 2023-2033 due to increased R&D activities, increased investment in the healthcare industry, and more government assistance,” says an analyst at FMI
Methodology Details Just a Click Away: https://www.futuremarketinsights.com/request-report-methodology/rep-gb-16243
Market Competition:
Key players in the Fuchs Endothelial Corneal Dystrophy (FECD) market are
- Kowa Pharmaceuticals
- Trefoil Therapeutics
- Alcon
- Emmecell
- Santen
- AJL Ophthalmic SA
- Massachusetts Eye and Ear
- KeraMed, Inc.
- Presbia Plc
In May 2022, SEGLENTIS® C-IV is now available for purchase through Kowa Pharmaceuticals America, Inc.
Key Segments Profiled in the Fuchs Endothelial Corneal Dystrophy (FECD) Market Industry Survey:
By Treatment:
- Phototherapeutic Keratectomy
- Amniotic Membrane Transplants
- Anterior Stromal Puncture
- Conjunctival Flaps
By Diagnosis:
- Slit-lamp Examination
- Molecular Genetic Tests
- Pachymetry
By End User:
- Hospitals
- ASCs
- Others
By Region:
- North America
- Latin America
- Western Europe
- Eastern Europe
- Asia Pacific
- Middle East & Africa (MEA)
Get a Purchase on the Report: https://www.futuremarketinsights.com/checkout/16243
About Future Market Insights (FMI)
Future Market Insights, Inc. (ESOMAR certified, recipient of the Stevie Award, and a member of the Greater New York Chamber of Commerce) offers profound insights into the driving factors that are boosting demand in the market. FMI stands as the leading global provider of market intelligence, advisory services, consulting, and events for the Packaging, Food and Beverage, Consumer Technology, Healthcare, Industrial, and Chemicals markets. With a vast team of over 400 analysts worldwide, FMI provides global, regional, and local expertise on diverse domains and industry trends across more than 110 countries.
Contact Us:
Future Market Insights Inc.
Christiana Corporate, 200 Continental Drive,
Suite 401, Newark, Delaware – 19713, USA
T: +1-845-579-5705
For Sales Enquiries: sales@futuremarketinsights.com
Website: https://www.futuremarketinsights.com
LinkedIn| Twitter| Blogs | YouTube